Skip to content

Sound Processing Innovations in Adult and Paediatric Cochlear Implant Recipients.

A Feasibility, Prospective, Repeated-measures Investigation to Investigate Innovations in Sound Processing in Adult and Paediatric Recipients Implanted With CE Approved Nucleus Cochlear Implants: an Umbrella Investigation.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05476328
Enrollment
8
Registered
2022-07-27
Start date
2020-01-22
Completion date
2023-03-17
Last updated
2025-02-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hearing Loss

Brief summary

This is a feasibility, prospective with sequential enrolment, multicenter, clinical investigation in adults and paediatrics with a CE approved Nucleus cochlear implant. Subjects older than 5 years will be included. Subjects will be screened and up to 120 eligible subjects will be recruited in the clinical investigation. Subjects will attend scheduled study visits over a period up to 5 years in different sub-studies as described in the sub-study documentation. A clinical setting can consist of therapeutic elements and evaluations. Subjects will be assessed with the commercially available Nucleus sound processor or via the xPC, NIC, etc. if required. Acute testing will be done where possible. Take home use will be applied when learning effects may play a significant role and to evaluate the acceptance of the new or improved sound coding algorithm or signal processing, in as many listening environments as possible. The subject might also be asked to complete questionnaires, to perform at-home tests etc. during this take home use and/or at the clinical visits. The time for a clinical visit will be limited to a maximum of 4 hours. The time in between clinical visits will vary with typical spacing of between 0 (acute) to 4 weeks. The goals of this umbrella investigation are to measure hearing outcomes to assess performance and/or to achieve higher convenience for implant users and hearing care professionals. The outcomes of the study will guide Cochlear to select features for inclusion in future Nucleus cochlear implant systems and/or future models of care.

Interventions

DEVICESPACE

SPACE (Spread Precompensation Advanced Combination Encoder) is a sound coding strategy that is intended to improve spectral resolution, and hence hypothesised to improve cochlear implant (CI) speech understanding in noise. It is an alternative to the ACE sound coding strategy. It has been implemented on the Nucleus 7 CP1000 sound processor for CIC4-based implants.

DEVICEOPAL-SPACE

OPAL-SPACE (combined OPAL and SPACE strategy) aims to preserve as many of the significant features encoded by both OPAL and SPACE strategies individually. Since SPACE codes spectral envelope information, while OPAL codes temporal periodicity information, it is reasonable to suggest that both coding techniques can be combined to improve perception additively.

DEVICEACE

Advanced Combination Encoder (ACE) is the commercially available, reference sound processing strategy.

DEVICECochlear Device Interface (CDI) Tool

For all strategies, programming will be performed using a research version of Custom Sound and the investigational software: Cochlear Device Interface Tool (CDI Tool). Investigational software will be used to stream stimulation sequences to a commercially available N6 sound processor using the Cochlear NIC4.1 interface.

Sponsors

Trium Clinical Consulting
CollaboratorINDUSTRY
Avania
CollaboratorINDUSTRY
Cochlear
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
5 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Users of a CE approved Nucleus cochlear implant, resulting in open set speech understanding. * Paediatrics: Older than 5 years and \<18 years when entering the study. (Belgium only) or * Adults: ≥18 years when entering the study (Belgium and Australia). * Subject/legally designated representative is fluent speaker in the language used for assessments. * Willing and able to provide written informed consent (for paediatric populations this criterion applies to the parent/ legally designated representative).

Exclusion criteria

* Unable or unwilling to comply with the requirements of the clinical investigation as determined by the investigator. * Additional health factors, known to the investigator, that would prevent or restrict participation in the audiological evaluations. * Investigator site personnel directly affiliated with this study and/or their immediate families; immediate family is defined as a spouse, parent, child, or sibling. * Cochlear employees or employees of Contract Research Organisations or contractors engaged by Cochlear for the purposes of this investigation. * Currently participating, or participated within the last 30 days, in another interventional clinical investigation/trial involving an investigational drug or device.

Design outcomes

Primary

MeasureTime frameDescription
Monosyllabic Word in Quiet Scores.One DayMonosyllabic word in quiet scores (for conventional Advanced Combination Encoders and new sound coding strategy). Resultant score is percentage of words repeated correctly. Possible scores ranges from 0% to 100% correctly repeated. Higher percentage score means better outcome

Countries

Australia, Belgium

Participant flow

Pre-assignment details

The participant flow includes only one group as this was a repeated measures, single-arm study where all participants were exposed to all sound processing strategies. Data from the same participants was collected multiple times across different conditions. The focus was on assessing effects within the same group under varying conditions, making it a single-arm design with repeated measurements on each participant.

Participants by arm

ArmCount
All Participants
Advanced Combination Encoder (ACE) sound processing strategy (reference strategy), Spread Precompensation Advanced Combination Encoder (SPACE), and Optimised Pitch and Language strategy-SPACE (OPAL-SPACE; combined OPAL and SPACE strategy) were evaluated in adult cochlear implant recipients. All strategies were programmed using a research version of Custom Sound and the investigational software: Cochlear Device Interface Tool (CDI Tool). SPACE: SPACE (Spread Precompensation Advanced Combination Encoder) is a sound coding strategy that is intended to improve spectral resolution, and hence hypothesised to improve cochlear implant (CI) speech understanding in noise. It is an alternative to the ACE sound coding strategy. It has been implemented on the Nucleus 7 CP1000 sound processor for CIC4-based implants. OPAL-SPACE: OPAL-SPACE (combined OPAL and SPACE strategy) aims to preserve as many of the significant features encoded by both OPAL and SPACE strategies individually. Since SPACE codes spectral envelope information, while OPAL codes temporal periodicity information, it is reasonable to suggest that both coding techniques can be combined to improve perception additively. ACE: Advanced Combination Encoder (ACE) is the commercially available, reference sound processing strategy. Cochlear Device Interface (CDI) Tool: For all strategies, programming will be performed using a research version of Custom Sound and the investigational software: CDI Tool.
8
Total8

Baseline characteristics

CharacteristicAll Participants
Age, Continuous69 years
Clinical Device in Test Ear
N7 CI24RE
3 Participants
Clinical Device in Test Ear
N7 CI512
5 Participants
Race and Ethnicity Not Collected— Participants
Sex: Female, Male
Female
3 Participants
Sex: Female, Male
Male
5 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 8
other
Total, other adverse events
0 / 8
serious
Total, serious adverse events
0 / 8

Outcome results

Primary

Monosyllabic Word in Quiet Scores.

Monosyllabic word in quiet scores (for conventional Advanced Combination Encoders and new sound coding strategy). Resultant score is percentage of words repeated correctly. Possible scores ranges from 0% to 100% correctly repeated. Higher percentage score means better outcome

Time frame: One Day

ArmMeasureGroupValue (MEAN)Dispersion
All ParticipantsMonosyllabic Word in Quiet Scores.ACE Strategy51 Percentage of words repeated correctlyStandard Deviation 14.97
All ParticipantsMonosyllabic Word in Quiet Scores.SPACE Strategy51.25 Percentage of words repeated correctlyStandard Deviation 10.95
All ParticipantsMonosyllabic Word in Quiet Scores.OPAL-SPACE Strategy48.50 Percentage of words repeated correctlyStandard Deviation 14.45

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026